NASDAQ : BBIO

BridgeBio Pharma, Inc.

$80.09 USD

-$2.05 (-2.5%)

Volume
2.12M
Average Volume
3.44M
Market Capitalization
$15.69B
P/E Ratio
-21.36
Dividend Yield
0.00%
Price Target
$100.00
Year High
$93.42
Year Low
$42.09
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.44
Company Overview

NASDAQ

Neil Kumar

Biotechnology

Healthcare

BBIO

839

US

USD

https://www.bridgebio.com

650 391 9740

10806X102

0001743881

Liquidity Metrics

-1.49

1.44

1.40

1.08

0.00

Sales & Valuation

$502.08M

27.05

-6.88

-34.54

-2.33

Profitability

-$3.79

-$729.31M

-125.17%

-126.20%

36.00%

-52.95%

P/E Metrics

-21.36

2.34

2.34

Analyst Price Target & Rating

$100.00

$130.00

$83.00

Sell

2/5

26 Analysts

-19.91%

Financial Health Scores

-2.23

2/9

$362.02M

$1.37B

$3.64B

-$617.74M

Key Metrics (TTM)

$18.19B

31.37

-29.88

1.44

36.00%

-57.94%

-4.65%

-2.89%

169 days

Company Executives
Name Title
Charles J. Homcy Co-Founder, Chairman of Pharmaceuticals & Lead Director
Neil Kumar Co-Founder, Chief Executive Officer & Director
Richard H. Scheller Chairman of Research & Development
Matthew Outten Chief Commercial Officer
Maricel Apuli Chief Accounting Officer
Uma Sinha Chief Scientific Officer
Eric Michael David Chief Executive Officer of Gene Therapy
Frank McCormick Co-Founder, Chairman of Oncology & Director
Eli Wallace Chief Scientific Officer of Oncology
Thomas Trimarchi Chief Financial Officer & President
Poll Results

No votes yet today — be the first to share your view!

About BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phas ... e 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

2026-07-28 11:06:46

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Affinity Asset Advisors LLC Has $11.14 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO

2026-07-25 04:05:31

Affinity Asset Advisors LLC cut its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 53.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the company's stock after selling 170,000 shares during the quarter.

California Public Employees Retirement System Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO

2026-07-24 04:11:26

California Public Employees Retirement System raised its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 21.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 253,479 shares of the company's stock after acquiring an additional 45,596 shares during the period. California Public Employees Retirement System

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

2026-07-23 14:16:15

BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

2026-07-22 07:30:00

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockbuster opportunity for BridgeBio - Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety and tolerability profile - BridgeBio is also currently enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial to study encaleret in pediatric ADH1 and intends to initiate the RECLAIM-HP Phase 3 registrational study of encaleret in chronic hypoparathyroidism later this summer; successful development could extend encaleret's utility to a broader patient population PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1).

Allspring Global Investments Holdings LLC Sells 104,864 Shares of BridgeBio Pharma, Inc. $BBIO

2026-07-18 03:11:15

Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 10.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 889,356 shares of the company's stock after selling 104,864 shares during the quarter. Allspring Global Investments Holdings

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

2026-07-13 12:25:30

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

2026-07-12 09:55:00

BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market.

Frequently Asked Questions

What is the current BridgeBio Pharma, Inc. (BBIO) stock price?

BridgeBio Pharma, Inc.(NASDAQ:BBIO) stock price is $80.09 in the last trading session. During the trading session, BBIO stock reached the peak price of $93.415 while $42.09 was the lowest point it dropped to. The percentage change in BBIO stock occurred in the recent session was --2.5% while the dollar amount for the price change in BBIO stock was -$2.05.

BBIO's industry and sector of operation?

The NASDAQ listed BBIO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BBIO?

Charles J. Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director
Neil Kumar | Co-Founder, Chief Executive Officer & Director
Richard H. Scheller | Chairman of Research & Development
Matthew Outten | Chief Commercial Officer
Maricel Apuli | Chief Accounting Officer

How many employees does BBIO have?

Number of BBIO employees currently stands at 839. BBIO operates from 3160 Porter Drive, Palo Alto, CA 94301, US.

Link for BBIO official website?

Official Website of BBIO is: https://www.bridgebio.com

How do I contact BBIO?

BBIO could be contacted at phone #650 391 9740 and can also be accessed through its website. BBIO operates from 3160 Porter Drive, Palo Alto, CA 94301, US.

How many shares of BBIO are traded daily?

The average number of BBIO shares traded daily for last 3 months was 3.44M.

What is the market cap of BBIO currently?

The market value of BBIO currently stands at $15.69B with its latest stock price at $80.09